ClinicalTrials.gg
Not yet recruitingNCT07201779REDCHIPUpdated Oct 1, 2025

Adaptation of REDCHIP Intervention for the Portuguese Context

An interventional study of REDCHiP and Treatment As Usual Control Group in Type 1 Diabetes, sponsored by ISPA - Instituto Universitario de Ciencias Psicologicas, Sociais e da Vida. Not yet recruiting. Open to participants aged 1 Year to 8 Years. Per ClinicalTrials.gov, last updated 2025-10-01.

Sponsored by ISPA - Instituto Universitario de Ciencias Psicologicas, Sociais e da Vida · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
1 Year to 8 Years
Sex
All
01

Study summary

The present Feasibility Randomized Controlled Trial (FRCT) aims to assess the acceptability and effectiveness of REDCHiP intervention, targeting parents of young children with T1D, followed in two major Portuguese hospitals. The objective of this trial is to evaluate (1) acceptability and feasibility by evaluating recruitment and retention rates, attendance throughout the sessions, and responses to parent satisfaction; (2) effectiveness by analyzing changes in parents' FH, diabetes distress (DD), emotional regulation (ER), resilient coping skills (RC), and anxiety and depression as well as changes in child glycemic outcomes (HbA1c, GMI, TBR, TIR, TAR) at three time points among participants allocated on intervention versus Treatment As Usual (TAU) group. Finally, (3) the investigators aim to qualitatively evaluate participant´s experiences and feedback regarding the REDHIP intervention through interviews.

Read the detailed description

One of the principal fears experienced by parents of young children with T1D is related to the occurrence of hypoglycemia episodes. These events can occur on a daily basis (i.e., often triggered by excessive exercise and/or prolonged periods without food intake) and can lead to severe acute consequences (i.e., seizures and coma) as well as long-term complications (i.e., cognitive decline). Moreover, young children often demonstrate reduced awareness for hypoglycemia and a limited ability to report its symptoms (i.e., sweating, shaking and dizziness) making it challenging for parents and other adult caregivers to detect and treat a hypoglycemic event. Combined these circumstances significantly contribute to heightened parental FH, which in some cases escalate into clinical phobia. In line with the theoretical model of caregiver fear of hypoglycemia, higher parental FH is frequently associated with avoidant behaviors and maladaptive coping strategies related to hypoglycemia. These patterns may contribute to persistently higher glycemic levels and increased variability, which, in turn, can serve as a catalyst for the development of T1D complications in their child. The literature has highlighted the potential impact of parental FH on children's glycemic outcomes and T1D management. It is also unclear whether routine use of an insulin pump or continuous glucose monitor can help to reduce FH in parents of very young children with T1D without the addition of psychological support, suggesting it is a high priority to design and test interventions to effectively treat parental FH, enhance parental well-being, and promote their T1D treatment engagement.

Thus, the original structure of the manualized REDCHiP intervention, is 10 video-based telehealth sessions (i.e.,7 group and 3 individual sessions with duration of 30 to 60 minutes). The present format of the Portuguese REDCHiP will have a 10 video-based telehealth sessions, all in group format, targeting parents of young children (≤ 8 years old) with T1D followed on two major hospitals in Lisbon, Portugal (i.e., Santa Maria Hospital and Dona Estefânia Hospital). This intervention is grounded in Cognitive Behavioral Therapy (CBT) principles, and is designed to address parents FH, and their avoidant coping behaviors related to FH. In addition, the sessions also focus on strengthening parents' coping strategies associated with T1D management and helping them to reduce feelings of diabetes distress Based on previous REDCHiP findings, and with the reported acceptability and feasibility of the intervention study, the investigators hypothesize that participants of intervention group will report lower levels of FH and better glycemic outcomes at immediate post-intervention compared to TAU group. The investigators anticipate group differences in these outcomes at three-month follow up. Furthermore, the investigators expect that REDCHiP will lead to improvements in all psychosocial adjustment factors (i.e., FH, DD, ER, RC, anxiety and depression) among all parents after receiving the REDCHiP intervention.

Accordingly, this protocol outlines the first attempt to culturally adapt and implement the telehealth REDCHiP intervention beyond the United States context.

02

Conditions studied

  • Type 1 Diabetes

Keywords

  • REDCHiP
  • Portuguese Context
  • Protocol
  • Psychological Interventions
  • Parents
  • Young Children
  • Type 1 Diabetes
  • Telehealth
03

In context

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

This study's planned enrollment of 44 is close to the median of 40 across 2,824 interventional studies indexed under Diabetes Mellitus, Type 1.

Browse Diabetes Mellitus, Type 1 studies →

Lead sponsor

ISPA - Instituto Universitario de Ciencias Psicologicas, Sociais e da Vida is the lead sponsor of 11 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year to 8 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Primary caregivers must have a young child aged ≤ 8 years with a confirmed diagnosis of T1D for at least three months;
  2. Young children must be using either an continuous subcutaneous insulin infusion (CSII) or multiple daily insulin injections (MDI) and continuous glucose monitoring (CGM) for daily T1D treatment;
  3. Parents must have internet access and a computer, tablet or smartphone that connects to the internet.

Exclusion criteria

Exclusion Criteria:

  1. Parents with severe psychiatric diagnosis;
  2. Families of children with another severe chronic condition (e.g., chronic kidney disease and Crohn's disease);
  3. Parents who are not fluent in Portuguese.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
44 participants (estimated)

Study arms

  • Experimental
    REDCHIP Intervention Group

    REDCHIP intervention group will receive 10 telehealth group sessions. CBT strategies are utilized to increase parents' awareness of any maladaptive thoughts and behaviors they may have related to FH (e.g., fear associated with in target glucose levels, reducing insulin to maintain higher glucose levels) and help them to adopt more adaptive coping skills. REDCHiP also includes content to improve participant's parenting skills and some T1D education to promote parents' knowledge and skills related to managing their young child's T1D

    Behavioral: REDCHiP

  • Active comparator
    Treatment As Usual Control Group

    These participants will receive the usual treatment provided during their medical appointments

    Other: Treatment As Usual Control Group

Interventions

  • BehavioralREDCHiP

    REDCHIP comprises 10 telehealth group sessions for parents of young children with T1D, is grounded in Cognitive Behavioral Therapy (CBT) principles, and is designed to address parents FH, and their avoidant coping behaviors related to FH. Sessions also focus on strengthening parents' coping strategies associated with T1D management and helping them to reduce feelings of diabetes distress.

  • OtherTreatment As Usual Control Group

    Participants will receive their treatment as usual in medical appointments

06

What researchers measure

Primary outcomes

  1. Parents Fear of Hypoglycemia

    Parents Fear of Hypoglycemia will be collected trough: The Hypoglycemia Fear Survey - Parents (HFS-P), 18-item self-report measure and comprises a total score and two subscales: Behavior and Worry.

    Time frame: From baseline to post-intervention (14-15 week)

  2. Parents Diabetes Distress

    Parents Diabetes Distress will be evaluated by, Parents The Problem Areas in Diabetes - Parent Revised (PAID-PR), 18-item self-report measure. It comprises two subscales: Immediate Burden and Theoretical Burden.

    Time frame: From baseline to post-intervention (14-15 week)

  3. Children Glycemic Outcomes

    Children´s Glycated Hemoglobin (HbA1c)

    Time frame: From baseline to post-intervention (14-15 week)

  4. Children Glycemic Outcomes

    Time in Range (TIR)

    Time frame: From baseline to post-intervention (14-15 week)

  5. Children Glycemic Outcomes

    Glucose Management Indicator (GMI)

    Time frame: From baseline to post-intervention (14-15 week)

  6. Children Glycemic Outcomes

    Time Bellow Range (TBR)

    Time frame: From baseline to post-intervention (14-15 week)

  7. Children Glycemic Outcomes

    Time Above Range (TAR)

    Time frame: From baseline to post-intervention (14-15 week)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Apr 2026, 0 months later.

Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 0 months is below that.

Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2025
First posted
Oct 1, 2025
StartEst.
Apr 2026
Primary completionEst.
Apr 2026
CompletionEst.
Dec 2026
Last update
Oct 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07201779
Lead sponsor
ISPA - Instituto Universitario de Ciencias Psicologicas, Sociais e da Vida
Collaborators
Hospital de Santa Maria, Portugal, Centro Hospitalar de Lisboa Central, Fundação para a Ciência e a Tecnologia, Nemours Children's Clinic
Responsible party
Vasco Vicente Costa (Principal Investigator, ISPA - Instituto Universitario de Ciencias Psicologicas, Sociais e da Vida) — Principal investigator
First posted
Oct 1, 2025
Start date
Apr 2026 (estimated)
Primary completion
Apr 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Oct 1, 2025

Study contacts

Vasco V Costa, MD
Contact
vcosta@ispa.pt
+351929374601
Vasco Costa
Contact
26054@alunos.ispa.pt
929374601
Vasco V Costa, MD
principal investigator · William James Center for Research (ISPA)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion